Table 1. Characteristics of the Patients at Baseline.*.
| Characteristic | Bamlanivimab plus Etesevimab (N=518) |
Placebo (N=517) |
Total (N=1035) |
|---|---|---|---|
| Age | |||
| Mean ±SD — yr | 54.3±17.1 | 53.3±16.4 | 53.8±16.8 |
| 65 yr or older — no. (%) | 168 (32.4) | 155 (30.0) | 323 (31.2) |
| Race or ethnic group — no./total no. (%)† | |||
| American Indian or Alaska Native | 2/512 (0.4) | 1/513 (0.2) | 3/1025 (0.3) |
| Asian | 16/512 (3.1) | 22/513 (4.3) | 38/1025 (3.7) |
| Black | 44/512 (8.6) | 39/513 (7.6) | 83/1025 (8.1) |
| Native Hawaiian or other Pacific Islander | 0 | 2/513 (0.4) | 2/1025 (0.2) |
| White | 449/512 (87.7) | 447/513 (87.1) | 896/1025 (87.4) |
| Multiple races or ethnic groups | 1/512 (0.2) | 2/513 (0.4) | 3/1025 (0.3) |
| Missing data | 6 | 4 | 10 |
| Hispanic or Latinx | 149/517 (28.8) | 155/516 (30.0) | 304/1033 (29.4) |
| Median body-mass index‡ | 34.14 | 33.90 | 34.09 |
| Peripheral oxygen saturation — no./total no. (%) | |||
| <96% | 90/516 (17.4) | 106/514 (20.6) | 196/1030 (19.0) |
| ≥96% | 426/516 (82.6) | 408/514 (79.4) | 834/1030 (81.0) |
| Risk of severe Covid-19 — no./total no. (%) | |||
| High | 493/518 (95.2) | 490/517 (94.8) | 983/1035 (95.0) |
| Low | 25/518 (4.8) | 27/517 (5.2) | 52/1035 (5.0) |
| Disease status — no. (%) | |||
| Mild Covid-19 | 397 (76.6) | 403 (77.9) | 800 (77.3) |
| Moderate Covid-19 | 121 (23.4) | 114 (22.1) | 235 (22.7) |
| Median days from symptom onset to randomization — no. (range) | 4 (0–29) | 4 (0–13) | 40 (0–29) |
| Mean viral load — Ct value§ | 23.98 | 23.97 | 23.97 |
*
Covid-19 denotes coronavirus disease 2019.
†
Race or ethnic group was reported by the patients, who could choose more than one category.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.
§
Ct denotes the cycle threshold on the reverse-transcriptase–polymerase-chain-reaction assay.